14 research outputs found
Hepatitis E in Italy : 5 years of national epidemiological, virological and environmental surveillance, 2012 to 2016
Increasing numbers of hepatitis E cases are being reported in several European countries, including Italy, but the burden of hepatitis E virus (HEV) infection is largely unknown in the latter. To gain a better understanding of HEV epidemiology at national level in Italy, we piloted a strengthened and integrated human (epi-demiological and virological) and environmental HEV surveillance system between 2012 and 2016. Over the 5-year period, 169 confirmed hepatitis E cases were identified, with a national annual incidence of 0.72 cases per 1,000,000. Of 65 HEV-RNA positive samples of sufficient quality for molecular analysis, 66% were genotype HEV3, 32% HEV1 and 1% HEV4. The most frequent risk factor reported by all HEV3 infected cases, was the consumption of undercooked pork and sausage. For the environmental surveillance, 679 urban sewage samples were collected from 53 wastewater treatment plants and HEV-RNA was detected in 38/679 of the samples. Among these, 25 (66%) were genotype HEV3 and the remaining were HEV1. We demonstrate that autochthonous transmission and environmental circulation of genotype HEV3 is adding to travel-related HEV transmission in Italy. We recommend the \u2018One Health\u2019 approach to integrated surveillance, and to include HEV-related messages within health information campaigns focussing on food security
Acute rhabdomyolysis and delayed pericardial effusion in an Italian patient with Ebola virus disease : a case report
Background: During the 2013-2016 West Africa Ebola virus disease (EVD) epidemic, some EVD patients, mostly health care workers, were evacuated to Europe and the USA. Case presentation: In May 2015, a 37-year old male nurse contracted Ebola virus disease in Sierra Leone. After Ebola virus detection in plasma, he was medically-evacuated to Italy. At admission, rhabdomyolysis was clinically and laboratory-diagnosed and was treated with aggressive hydration, oral favipiravir and intravenous investigational monoclonal antibodies against Ebola virus. The recovery clinical phase was complicated by a febrile thrombocytopenic syndrome with pericardial effusion treated with corticosteroids for 10days and indomethacin for 2months. No evidence of recurrence is reported. Conclusions: A febrile thrombocytopenic syndrome with pericardial effusion during the recovery phase of EVD appears to be uncommon. Clinical improvement with corticosteroid treatment suggests that an immune-mediated mechanism contributed to the pericardial effusion
MIGLIORAMENTI NELLA DETERMINAZIONE DEI GENOTIPI HCV MEDIANTE L’UTILIZZO DEL VERSANT HCV GENOTYPE 2.0 (INNO-LIPA HCV 2.0)
I TEST MOLECOLARI AD AMPIA LINEARITÀ ED ELEVATA SENSIBILITÀ PER LA DETERMINAZIONE DELLA CARICA VIRALE: CONFRONTO TRA VECCHI E NUOVI METODI
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes.
Abstract. Background: A good correlation between HCV core antigen (HCVAg) and different HCV-RNA assays has been
described, but little data are available in HCV/HIV co-infection. We aimed to evaluate HCVAg in comparison with
HCV-RNA and to determine their kinetics during antiviral treatment in selected HCV/HIV co-infected patients.
Methods: 355 samples from 286 HCV/HIV co-infected subjects for whom HCV-RNA (Abbott RealTime) was
requested were analysed also for HCVAg (Abbott ARCHITECT) in order to evaluate the correlation between the two
parameters both in patients treated or untreated for chronic hepatitis C and according to different HCV genotypes.
The differences between percentages were evaluated by chi square or Fisher’s exact test, while mean and median
values were compared by Student’s t test or the Mann–Whitney test, respectively. All differences were considered
significant for a p value <0.05.
Results: HCVAg was detectable on 288/315 sera (91.4%) positive for HCV-RNA and in 5 out of40 (12.5%) sera with
undetectable HCV-RNA for a total concordance of 90.1%. The correlation was fair both in untreated (r = 0.742) and
in treated (r = 0.881) patients and stronger for genotypes 1 and 4 than for genotype 3. Both HCV-RNA and HCVAg
levels were significantly higher (p = 0.028 and p = 0.0098, respectively) in patients infected by genotype 1 than by
genotype 3. The mean ratio of Log values between HCV-RNA (IU/mL) and HCVAg (fmol/liter) was 2.27 ± 1.09 in
untreated and 2.20 ± 0.82 in treated patients (p = n.s.),consistent with a sensitivity of HCVAg corresponding to about
1,000 IU/mL of HCV-RNA, and ranged from 2.21 to 2.32 among HCV genotypes with no significant differences; five
samples (1.4%; 2 genotype 1a or 1c, 3 genotype 3a) showed highly divergent values. The analysis of 18 monitoring
profiles from patients treated with PEG-IFN and Ribavirin showed similar trends, except in one case in which relapse
could be predicted by HCVAg and not by HCV-RNA.
Conclusion: These results suggest that HCVAg represents an adequate tool for determining an ongoing HCV
infection also in HIV co-infected patients, with lower costs and faster turnaround time than HCV-RNA
Detection of TT virus in lymph node biopsies of B-CELL lymphoma and Hodgkin's disease, and its association with EBV infection
Human TT virus (TTV) recently isolated from the serum of a patient with post-transfusion hepatitis does seem to have only hepatopathic effect. The virus can also infect the serum, peripheral blood mononuclear cells (PBMC) and bone marrow cells (BMC). Additional evidence has indicated that TTV is also present in the serum of people with hematopoietic malignancies. A significant increase in the incidence of lymphoma has recently been observed worldwide. We have investigated the presence of TTV DNA in lymph node biopsies of Italian patients affected with the most common lymphoma types in Western Countries: follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and nodular sclerosis Hodgkin's disease (NS-HD). The possible role of a co-infection with Epstein-Barr virus (EBV) has also been investigated. DNA was extracted from 73 paraffin-embedded and 38 snap-frozen tissue specimens. From these, only 67 samples (29 paraffin-embedded and 38 snap-frozen tissues) from a total of 56 patients, were suitable for PCR analysis. TTV and EBV were detected by PCR using primers from two different conserved region in TTV and EBV genomes respectively. TTV DNA was detected in 30.0-50.0% of FL, 30.8% of DLBCL and 30.0-50.0% of NS-HD cases, depending on the primers used. All cases of non-specific reactive lymphoid hyperplasia (RLH), used as a putative control, were negative. The two major TTV genotypes circulating in Italy (G1 and G2) were detected in the analysed lymphoid neoplasms. EBV DNA was detected in 40.0% of FL, in 72.7% of DLBCL, in 80.0% of SN-HD and in 40.0% of RLH cases. EBV co-infection was found in 90% of TTV positive cases. The in situ hybridization assay was performed in TTV positive frozen samples. The significant prevalence of TTV DNA in lymphocytes circulating in the lymph nodes of both B-cell lymphomas and HD reported herewith suggests a possible implication of TTV infection in the development of these lymphoproliferative disorders